The mission of PT Kalbe Farma Tbk. ("Kalbe") is to assist Indonesians to achieve a higher quality of life by providing them with products that improve their health and well-being. The Company's main areas of business activities are the production, distribution, marketing and packaging of pharmaceuticals, health foods and other consumer products. In order to facilitate these activities, it currently operates four main divisions: Pharmaceuticals, Health Food, Packaging and Distribution. Of these divisions, in 2005, Pharmaceuticals contributed to 53% of net revenues, Health Food 17%, Packaging 4% and Distribution 26%. Kalbe was established in 1966. While it has remained consistently focused on achieving its stated mission, it has undergone significant changes throughout its period of operation in order to continue to serve the evolving and developing needs of Indonesian consumers. In particular, while it continues to develop a broad range of Over-The- Counter (OTC) drugs, it has placed increasingly greater emphasis on its ability to provide a more extensive array of value-added generic and licensed drugs. It is also placing increasing emphasis on its role as an innovator, developing new drugs and chemical entities either by itself or in alliance with strategic partners internationally. In order to achieve its mission, Kalbe places a strong degree of emphasis on strict adherence to internationally established standards, both in terms of production quality and management practices. Kalbe's commitment to such standards has been recognized by a number of certifying agencies through their numerous awards. All of Kalbe's production facilities and those of its Subsidiaries have achieved ISO 9001 certification, while Kalbe, PT Dankos Laboratories Tbk. ("Dankos") and PT Bintang Toedjoe have achieved ISO 14001 and OHSAS 18001/SMK3 (Work Safety Standards) certification. Kalbe and Dankos have consistently maintained high rankings for its implementation of the principles of Good Corporate Governance, ranking number five and two respectively amongst all companies publicly listed on the Jakarta Stock Exchange in 2005. On December 16, 2005, the management of Kalbe effected the merger of Dankos and PT Enseval ("Enseval") into the company to create the largest publicly listed pharmaceutical company in Southeast Asia. This merger will provide a strong basis for Kalbe's future growth by facilitating economies of scale and improved efficiency and effectiveness.

Vision: To be the best Indonesian global healthcare company driven by innovation, strong brands, and excellent management. Mission: To improve health for a better life. Motto: The Scientific Pursuit of Health for a Better Life Other Information PT. Kalbe Farma TBK. Terima ASEAN Business Award (21-Nov-2007) Kalbe.co.id - PT. Kalbe Farma Tbk. (Kalbe), perusahaan farmasi Indonesia, menerima penghargaan ASEAN Business Award sebagai pemenang pertama untuk kategori Corporate Social Responsibility pada acara ASEAN Business and Investment Summit 2007 yang diselenggarakan di Singapura tanggal 18 November 2007.